MiNK Therapeutics (INKT) announced that new translational data supporting the role of invariant natural killer T cells in idiopathic pulmonary fibrosis were presented at the Emerging Cell Therapies Meeting of the Keystone Symposia on Molecular and Cellular Biology, taking place February 1-4, in Banff, Alberta, Canada. The data demonstrate a significant depletion of invariant natural killer T cells in lung-associated lymph nodes from patients with end-stage idiopathic pulmonary fibrosis, supporting a mechanistic role for iNKT insufficiency in advanced disease.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INKT: